Q-omics provides the consensus-scored COQ5 profile across patient tissues and cancer cell-line models. COQ5 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, COQ5 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, COQ5 RNA expression shows 18,187 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight HNSC, THCA, and ACC as cancer lineages where COQ5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for COQ5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes COQ5 survival associations across molecular data types. COQ5 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible COQ5 RNA expression–survival associations across cancer types. High COQ5 expression shows unfavorable associations in HNSC, MESO, ACC, BLCA and KICH, but favorable associations in BRCA. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for COQ5 RNA expression.
This table summarizes COQ5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for COQ5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. COQ5 shows lower tumor expression in THCA and KICH and higher tumor expression in LIHC, BLCA, STAD and LUSC. The THCA box plot shows higher COQ5 RNA expression in normal versus tumor tissue (log2 FC = −0.660, t-test p < 0.001).
This table shows molecular features associated with COQ5 in patient tissues and cancer cell lines. In patient samples, COQ5 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, COQ5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and UPPER_AERODIGESTIVE_TRACT.
